Gritstone Bio Inc (NAS:GRTS)
$ 0.8179 0.0305 (3.87%) Market Cap: 88.80 Mil Enterprise Value: 142.47 Mil PE Ratio: 0 PB Ratio: 5.84 GF Score: 30/100

Gritstone bio Inc Key Opinion Leader Webinar on Neoantigen Oncology Programs Transcript

Aug 18, 2021 / 03:00PM GMT
Release Date Price: $8.47 (-2.42%)
Tara Sobierajski

Good morning and welcome to the Gritstone Bio KOL Webinar on Neoantigen Oncology Programs and Colorectal Cancer. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Gritstone Bio website following the conclusion of the event.

I'd now like to turn the call over to your host, Dr. Andrew Allen, Co-Founder, President and Chief Executive Officer of Gritstone Bio. Please go ahead, Andrew.

Andrew R. Allen
Gritstone bio, Inc. - Co-Founder, President, CEO & Director

Very good. Thank you, Tara. Good morning, everybody. This is Andrew Allen. I'm the CEO, as you heard, one of the founders of Gritstone Bio, and I'll be making some forward-looking statements during this presentation.

We'll be spending the next hour covering a couple of important topics. I'll begin with a brief overview of the Gritstone Bio neoantigen immunotherapy program with a focus on the personalized program called GRANITE, which will be presenting data at ESMO in September, just a month or so away. I'll give

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot